Illumina employees have been showing their commitment to early cancer detection and advancing research and treatment by ...

Illumina is a prominent entity in the genomic sequencing market, providing advanced DNA sequencing ... The favorable court ...

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related ...

New strategies promise to streamline workflows, conserve consumables, increase productivity, and enhance reproducibility.

The Human Genome Project described the first (almost) complete reference genome, but it didn’t say much about human variation ...

Illumina employees have been showing their commitment to early cancer detection and advancing research and treatment by getting involved in the company's recently concluded Steps Against Cancer ...

Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ETCorporate ParticipantsSalli Schwartz - Vice President of ...

Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conferences: ...

Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basis Core Illumina GAAP operating margin of 68.6% and non-GAAP ...